Cure My Disease

Don't miss your cure!

 Log in / Sign up

Shorter, personalized radiation may target endometrial cancer with fewer side effects

NCT ID NCT07116213

Disease control Sponsor: Xiaorong Hou Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 16, 2026 · Last updated Sep 17, 2026 · Updated 1 time

Summary

Researchers are testing a shorter, adapted form of radiation therapy for people with high-risk endometrial cancer after surgery. The trial enrolls 20 patients and uses daily imaging to adjust the radiation plan to each person's anatomy. Participants receive moderately hypofractionated external beam radiation, with optional brachytherapy and chemotherapy. The study tracks acute and long-term side effects, three-year failure-free survival, quality of life, and treatment costs.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
moderately hypofractionated adaptive radiotherapy
What this could lead to
If it works, this approach could offer a shorter, more personalized course of radiation after surgery for high-risk endometrial cancer, with fewer side effects and lower costs.
What could go wrong
This is a small, single-arm study with 20 patients and no control group, so it cannot prove the approach is better than standard radiation. Results may not apply to all patients, and radiation still carries risks of bowel, bladder, or other pelvic side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 20 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jun 2025

Expected to finish

Dec 2030

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 70 years

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age : 18-70 years old. * Performance Status : ECOG score 0-2. * Expected to comply with oART (Online Adaptive Radiotherapy) workflow. * Initial Surgical Treatment : Total hysterectomy and bilateral salpingo-oophorectomy ± Pelvic and/or para-aortic lymph node dissection/sampling or sentinel lymph node biopsy. * Pathological Staging \& Histology (per FIGO 2009): Stage I : Grade 3 endometrioid adenocarcinoma with superficial myometrial invasion and extensive LVSI (Lymphovascular Space Invasion). Grade 2 endometrioid adenocarcinoma with deep myometrial invasion and extensive LVSI. Grade 3 endometrioid adenocarcinoma with deep myometrial invasion. Stage II-IIIC1 : Endometrioid carcinoma. Stage I-IIIC1 : Serous carcinoma or clear cell carcinoma. * Informed Consent : * Patients and families fully understand the study protocol. * Voluntarily participate and sign informed consent forms before enrollment Exclusion Criteria: * Prior Radiotherapy : History of abdominal or pelvic irradiation. * Treatment Interval : Without adjuvant chemotherapy: \>12 weeks between surgery and radiotherapy initiation. With adjuvant chemotherapy: \>6 months between surgery and radiotherapy initiation. * Malignancy History : Prior diagnosis of other malignancies. * Pregnancy/Lactation : Pregnant or breastfeeding women. * Active Infection : Fever or uncontrolled active infection. * Inflammatory Bowel Disease (IBD) : History of IBD (regardless of activity status). * Comorbidities : Severe conditions affecting trial compliance, including: Unstable cardiac disease requiring treatment, renal impairment, chronic hepatitis, poorly controlled diabetes, psychiatric disorders

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Endometrial cancer are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

endometrial cancer endometrium neoplasm neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Endometrial cancer Hypofractionated dose Radiotherapy, adjuvant Side effects Survival , tumor

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Peking Union Medical College Hospital

    RECRUITING

    Beijing, Beijing Municipality, 100730, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.